FDA fast track covers ART6043 plus olaparib in PARP inhibitor–naïve gBRCAm, HER2-negative locally advanced/metastatic breast ...
A whopping 85% of men experience significantly thinning hair by age 50, and two-thirds experience noticeable hair loss by age 35. So, while Hims provides access to a number of different prescription ...
Red light therapy has come a long way since then. Rahman explained that red light wavelengths activate the mitochondria in skin cells and increase blood flow to hair follicles. This uptick in ...
PDUFA action date set for August 23, 2026If approved, DTX401 will be the first treatment to address the underlying cause of GDSIaNOVATO, Calif., ...
Those of us who watch the Olympics as bystanders tend to smugly judge athletes for succumbing to pressure without ...
Eating fibre can improve health, lengthen lifespans, and even protect our brains. Yet many of us are still coming up short on this “essential nutrient”.A diet high in wholegrains, fruits, pulses, nuts ...
In India, rare diseases are not so rare. It is estimated that around 70 million Indians live with one of more than 7,000 rare ...
Exercise Milk Intake Linked to Better Bone Density After 60: StudyA recent study published in the Journal of Nutrition, Health and Aging ...
Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced that its Biologics License Application (BLA) ...
The FDA is now expected to decide on the application by Aug. 23. ・The company intends to manufacture the therapy at its new gene therapy manufacturing facility in Bedford, Massachusetts, if approved.
U.S. Fast Track designation of ART6043 underpinned by promising clinical data to date and high unmet need in gBRCA-mutated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results